NOV 09, 2017 12:00 PM PST

Understanding T Cell Responses in Tuberculosis-Latest research on QuantiFERON-TB Gold Plus

Speaker

Abstract

QuantiFERON TB (QFT) was the first interferon gamma release assay (IGRA) utilizing whole blood stimulation as a test for TB infection, gaining FDA approval in 2001. Subsequently there have been several improvements to the first test in terms of accuracy, ease of use and clinical utility.  There are currently over 1200 independent publications on QFT and it is the most studied IGRA in the world on contact evaluation, epidemiology, vaccine and Pharma development and biomarker research. The 4th generation (QFT-Plus) is currently FDA approved in the USA and is CE marked in Europe. QFT-Plus provides higher specificity than the tuberculin skin test (TST) by incorporating highly specific antigens that do not cross react with BCG and most environmental non tuberculosis mycobacteria. In addition, it has new antigens that stimulate CD8 T cells.

Published studies now supports a role for CD8+ T cells participating in the host defense to MTB by producing IFN-γ and other soluble factors, which activate macrophages to suppress growth of MTB, kill infected cells, or directly lyse intracellular MTB (1-3). MTB-specific CD8+ cells have been detected in subjects with LTBI and with active TB disease where IFN-γ producing CD8+ cells may be frequently found (4-6). Moreover, ESAT-6 and CFP-10 specific CD8+ T lymphocytes are described as being more frequently detected in subjects with active TB disease versus LTBI, and may be associated with a recent MTB exposure (7-9). In addition, MTB-specific CD8+ T cells producing IFN-γ have also been detected in active TB subjects with HIV co-infection (10, 11) and in young children with TB disease (12).  How the incorporation of novel CD8 antigen stimulation technology has proved beneficial in independent performance studies with QFT-Plus in active TB and contact investigations will be discussed.  Maintaining the performance and ease of use of whole blood stimulation builds on the value of QFT and will provide further benefit in the management of latent tuberculosis and TB control programs.


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
NOV 09, 2017 12:00 PM PST

Understanding T Cell Responses in Tuberculosis-Latest research on QuantiFERON-TB Gold Plus


Specialty

Immunology

Infectious Disease

Diagnostics

Cell Biology

Pcr/rt-Pcr/real-Time Pcr

Biomarkers

Biotechnology

Biochemistry

Microbiology

Laboratory Testing

Cell Culture

Antibodies

Clinical Diagnostics

Clinical Research

Assay Development

Geography

North America44%

South America44%

Africa11%

Registration Source

Website Visitors100%

Job Title

Medical Laboratory Technician38%

Research Scientist25%

Clinical Laboratory Scientist25%

Facility/Department Manager13%

Organization

Government/public44%

Diagnostic Company22%

Non-Profit Organization11%

Clinical Laboratory11%

Government11%


Show Resources
Loading Comments...
Show Resources